Acceleron Pharma Inc. (XLRN) Trading at $48.60 after Move Up

June 29, 2018 - By Leslie Harms

Acceleron Pharma Inc. (NASDAQ:XLRN) Corporate Logo

During 2018 Q1 the big money sentiment increased to 1.27. That’s change of 0.18, from 2017Q4’s 1.09. 13 investors sold all, 39 reduced holdings as Acceleron Pharma Inc. ratio increased. 42 rose holdings while 24 funds took holdings. Funds hold 38.30 million shares thus 0.44% more from 2017Q4’s 38.14 million shares.
Polar Cap Limited Liability Partnership holds 0.42% in Acceleron Pharma Inc. (NASDAQ:XLRN) or 1.07M shs. Vanguard Grp Inc has invested 0% of its capital in Acceleron Pharma Inc. (NASDAQ:XLRN). Public Employees Retirement Association Of Colorado reported 3,246 shs or 0% of all its holdings. Sg Americas Securities Ltd Liability Corporation has 0% invested in Acceleron Pharma Inc. (NASDAQ:XLRN). 462,245 are held by Great Point Prtnrs Lc. Aqr Mgmt Ltd Liability owns 0% invested in Acceleron Pharma Inc. (NASDAQ:XLRN) for 9,537 shs. Bailard Inc holds 0.03% of its capital in Acceleron Pharma Inc. (NASDAQ:XLRN) for 10,500 shs. California State Teachers Retirement System stated it has 0% of its capital in Acceleron Pharma Inc. (NASDAQ:XLRN). Nelson Van Denburg And Campbell Wealth Group Inc Limited Liability Corporation stated it has 0.03% of its capital in Acceleron Pharma Inc. (NASDAQ:XLRN). Timessquare Capital has invested 0.09% in Acceleron Pharma Inc. (NASDAQ:XLRN). 1.40M were reported by Farallon Ltd Liability Company. Geode Cap Ltd Liability Corporation invested in 0% or 365,338 shs. Legal & General Group Inc Public Limited has 14,454 shs. Moreover, Utd Services Automobile Association has 0.01% invested in Acceleron Pharma Inc. (NASDAQ:XLRN) for 103,861 shs. Alliancebernstein Lp owns 89,400 shs or 0% of their US capital.

Acceleron Pharma Inc. registered $4.08 million net activity with 0 buys and 12 insider sales since January 2, 2018. 37,500 shs were sold by POPS RICHARD F, worth $1.55M on Tuesday, March 6. On Tuesday, January 2 Shares for $182,363 were sold by Kumar Ravindra. $153,792 worth of Acceleron Pharma Inc. (NASDAQ:XLRN) was sold by MCLAUGHLIN KEVIN F. On Wednesday, January 3 Sherman Matthew L sold $197,868 worth of Acceleron Pharma Inc. (NASDAQ:XLRN) or 4,633 shs. 2,266 shs were sold by Rovaldi Christopher, worth $96,134 on Tuesday, January 2.

Acceleron Pharma Inc. (NASDAQ:XLRN) increased significantly to $48.60. On Jun, 29 the move was announced by Barchart.com. It has $2.23 billion MC. The company’s valuation will be $66.75M more at $50.06 target.

Acceleron Pharma Inc. (NASDAQ:XLRN) is anticipated to reveal earnings on August, 2., as reported by Faxor. Analysts expect change of 16.88 % or $0.13 from previous year’s $-0.77 EPS compared to current’s $-0.64 EPS. Analysts at Wall Street see Acceleron Pharma Inc.’s 10.34 % negative EPS growth compared to $-0.58 EPS for last quarter.

Acceleron Pharma Inc. (NASDAQ:XLRN) Ratings Coverage

In total 7 analysts cover Acceleron Pharma (NASDAQ:XLRN). “Buy” rating has 5, “Sell” are 0, while 2 are “Hold”. 71% are bullish. 9 are the (NASDAQ:XLRN)’s analyst reports since January 8, 2018 according to StockzIntelligence Inc. The stock rating was upgraded by JP Morgan to “Overweight” on Monday, February 26. On Thursday, March 1 Citigroup maintained Acceleron Pharma Inc. (NASDAQ:XLRN) rating. Citigroup has “Buy” rating and $63 target. The company rating was maintained by Credit Suisse on Friday, June 29. On Friday, June 29 the firm earned “Neutral” rating by Goldman Sachs. On Wednesday, February 28 the firm has “Buy” rating by H.C. Wainwright given. In Wednesday, February 28 report Barclays Capital maintained the stock with “Overweight” rating. On Monday, January 8 H.C. Wainwright initiated the shares of XLRN in report with “Buy” rating. In Tuesday, May 22 report Oppenheimer initiated the stock with “Hold” rating. On Wednesday, March 28 the rating was initiated by H.C. Wainwright with “Buy”.

For more Acceleron Pharma Inc. (NASDAQ:XLRN) news published briefly go to: Streetinsider.com, Globenewswire.com, Seekingalpha.com, Benzinga.com or Benzinga.com. The titles are as follows: “Form 8-K ACCELERON PHARMA INC For: Jun 15” published on June 20, 2018, “Market Trends Toward New Normal in RCI Hospitality, Phillips 66 Partners LP, Acceleron Pharma, Destination …” on June 22, 2018, “Acceleron: Luspatercept New Data Is A Buy Signal” with a publish date: June 07, 2018, “Acceleron Pharma Rallies After Phase 3 MDS Data, But Goldman Sachs Still Isn’t Buying” and the last “Benzinga’s Top Upgrades, Downgrades For June 29, 2018” with publication date: June 29, 2018.

Acceleron Pharma Inc., a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for serious and rare diseases.The firm is worth $2.23 billion. The Company’s therapeutic candidates include luspatercept to treat anemia and associated complications in patients with myelodysplastic syndromes and beta-thalassemia; and sotatercept for chronic kidney diseases.Last it reported negative earnings. The companyÂ’s therapeutic candidates also include dalantercept, a tyrosine kinase inhibitor, which is in phase II clinical trials for renal cell carcinoma; and ACE-083 that is in phase II clinical trials for facioscapulohumeral dystrophy.

Acceleron Pharma Inc. (NASDAQ:XLRN) Analyst Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.





Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: